Xtant Medical (XTNT) Stock Price, News & Analysis

Company Overview

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.

Key Stats

• Today's Range: $0.53 to $0.54
• 50-Day Range: N/A
• 52-Week Range: $0.51 to $1.45
• Volume: 15,226 shs
• Average Volume: 99,680 shs
• Market Capitalization: $70.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.25
• Consensus Rating: Buy

Xtant Medical Stock Analysis - MarketRank™

Xtant Medical scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Xtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Xtant Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Xtant Medical is -27.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xtant Medical is -27.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xtant Medical has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.42% of the float of Xtant Medical has been sold short.

Short Interest Ratio / Days to Cover

Xtant Medical has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xtant Medical has recently decreased by 6.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xtant Medical does not currently pay a dividend.

Dividend Growth

Xtant Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.42% of the float of Xtant Medical has been sold short.

Short Interest Ratio / Days to Cover

Xtant Medical has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xtant Medical has recently decreased by 6.95%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Xtant Medical has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Xtant Medical this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xtant Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.70% of the stock of Xtant Medical is held by insiders.

Percentage Held by Institutions

69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XTNT Stock Analysis - Frequently Asked Questions

How were Xtant Medical's earnings last quarter?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) issued its quarterly earnings data on Thursday, August, 8th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.01. The medical device company had revenue of $29.94 million for the quarter. Xtant Medical had a negative trailing twelve-month return on equity of 6.71% and a negative net margin of 3.00%.

When did Xtant Medical's stock split?

Xtant Medical shares reverse split before market open on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Xtant Medical's major shareholders?

Xtant Medical's top institutional investors include Evernest Financial Advisors LLC (0.03%). Insiders that own company stock include Stavros G Vizirgianakis, Sean E Browne and Scott C Neils.
View institutional ownership trends.

How do I buy shares of Xtant Medical?

Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Xtant Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xtant Medical investors own include Meta Platforms (META), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Tesla (TSLA) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:XTNT
• Previous Symbol: AMEX:XTNT
• CUSIP: N/A
• CIK: 1453593
• Web: xtantmedical.com
• Phone: (406) 388-0480
• Fax: 406-388-1354
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.25
• High Stock Price Target: $3.00
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +322.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $660,000.00
• Net Margins: -3.00%
• Pretax Margin: -4.46%
• Return on Equity: -6.71%
• Return on Assets: -3.56%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 2.44
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: $91.30 million
• Price / Sales: 0.76
• Cash Flow: $0.03 per share
• Price / Cash Flow: 18.54
• Book Value: $0.39 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 130,310,000
• Free Float: 117,674,000
• Market Cap: $69.48 million
• Optionable: Not Optionable
• Beta: 0.39